Replimune’s Twice‑Rejected Melanoma Drug Prevails in FDA Adcomm Vote on July 31, 2026 Advanced Melanoma Advisory Committees Cellular Tissue gene therapy melanoma drug nivolumab Opdivo Replimune RETINITIS PIGMENTOSA 1 United States Food and Drug Administration vusolimogene oderparepvec +